Six-Month HIV Prevention Shot Achieves 99% Efficacy in Major Study
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
Vaccines can put an end to HIV. African governments must take the lead in developing them
As medical scientists working in HIV prevention, we believe that HIV vaccines will be critical to eliminating HIV ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to be effective.When lenacapavir test results were presented at a World AIDS ...
clinicaltrialsarena3d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
'Huge relief' as new drug found to effectively prevent HIV infection
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...
The New England Journal of Medicine5d
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP ...
A Moment Of Reckoning In The Fight Against HIV
Ending AIDS as a public health threat by 2030 is a real possibility, tantalizingly close. But the job is not yet done.
Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...